Results 141 to 150 of about 276,902 (250)

Response to benralizumab in patients with severe eosinophilic asthma. [PDF]

Rev Med Inst Mex Seguro Soc
Velasco-Santos JI, Núñez-Martínez FJ, Martínez-Sánchez BH, Chávez-Lárraga AJ.   +3 more
europepmc   +1 more source

Update on new biologics for intractable eosinophilic asthma: impact of reslizumab

, 2018
Jagdeep Sahota,1 Douglas S Robinson2 1Department of Respiratory Medicine, University College London, London, UK; 2Department of Respiratory Medicine, University College Hospital NHS Trust, London, UK Abstract: A small percentage of patients with asthma
Sahota J, Robinson DS
core  

Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma. [PDF]

Respir Res
Papavassiliou KA, Gogou VA, Papavassiliou AG.   +2 more
europepmc   +1 more source

Non-eosinophilic asthma: mechanisms and treatment

Asthma causes a unique type of inflammation in the airways. Until recently, the cell responsible for this inflammation was thought to be the eosinophil.

core  

Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment. [PDF]

J Clin Med
Pastore D, Lupia C, Chiarella E, Piazzetta GL, Mazza G, Neri G, Petrone A, Bruni A, Longhini F, Garofalo E, Pelaia G, Pelaia C.   +11 more
europepmc   +1 more source

Preventive Application of House Dust Mite‐Sublingual Immunotherapy Induces Blocking Antibodies in Sensitized Preschool Children

Allergy, EarlyView.
HDM‐pSLIT induced IgG, IgG1, and IgG4 specific to major HDM allergens in sensitized non‐allergic preschool children without increasing HDM‐sIgE. It blunted the development of new sensitizations and reduced HDM reactivity in skin and basophils. HDM‐pSLIT treated children displayed a blocking effect on HDM‐induced basophil activation.
Varsha Dwivedi, Klara Schmidthaler, Hilal Demir, Justyna Sieber, René Gaupmann, Livia Mia Gona‐Höpler, Christina Bannert, Saskia Gruber, Eleonora Dehlink, Thomas Eiwegger, Alexandra Graf, Barbara Bohle, Zsolt Szépfalusi   +12 more
wiley   +1 more source

Mapping Allergen B‐ and T‐Cell Epitopes: Technological Advances and Their Role in Precision Allergy Therapy

Allergy, EarlyView.
ABSTRACT Allergic diseases arise from aberrant immune recognition of otherwise harmless environmental proteins and are driven by epitope‐specific interactions between allergens and the adaptive immune system. Although component‐resolved diagnostics have improved molecular characterisation of sensitization, they remain limited to whole‐allergen ...
Mark Møiniche, Josefine Corneliussen, Kristoffer H. Johansen, Alexandre Ruiz‐Carrasco, Caroline Paulsen, Yuchen Li, Carolina Barra, Sandhya Bangaru, Monica L. Fernández‐Quintero, Ewa Bartko, Lars Blom, Esperanza Rivera‐de‐Torre   +11 more
wiley   +1 more source

Clinical diagnosis and treatment of eosinophilic asthma by respiratory physicians in China: a cross-sectional survey. [PDF]

J Thorac Dis
Deng Y, Kong X, Chen Y, Jiang M, Yu L, Xie J.   +5 more
europepmc   +1 more source

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions

Allergy, EarlyView.
Human Tc2 cells exhibit a metabolically active phenotype characterized by enhanced glycolysis, mitochondrial respiration, and fatty acid uptake dependent on PPARγ. Alarmins strongly amplify IL‐5 and IL‐13 production in Tc2 cells, supporting a shared immunometabolic program across type 2 lymphocytes.
Sabrina de Souza Ferreira, Lisa Holla, Sophia Björkander, Marie Kaarup Bek, Lorenz Wirth, Patrick A. Shearer, Jesper Säfholm, Erik Sachs, Mamdoh Al‐Ameri, Kasra Vali, Sandra Ekström, Erik Melén, Jenny Mjösberg, Christopher Andrew Tibbitt   +13 more
wiley   +1 more source

Impact of IL-5 Pathway Inhibition on Circulating Eosinophil- and Remodeling-Related Biomarkers in Severe Eosinophilic Asthma. [PDF]

J Asthma Allergy
Damiański P, Kumor-Kisielewska A, Białas AJ, Kuna P, Kupczyk M.   +4 more
europepmc   +1 more source